You are here:Home-Antibodies & Recombinant Proteins-Biosimilar Antibody-Zimberelimab
Zimberelimab

Chemical Structure : Zimberelimab

CAS No.:

Zimberelimab (GLS-010, AB122)

Catalog No.: PC-38874Not For Human Use, Lab Use Only.

GLS-010 (Zimberelimab, AB122) is a fully human, monoclonal immunoglobulin G4 (IgG4) anti-programmed death-1 (PD-1) antibody that shows promising efficacy and safety in advanced solid tumors.

Packing Price Stock Quantity
1 mg Get quote
5 mg Get quote
10 mg Get quote
25 mg Get quote
100 mg Get quote

Bulk size, bulk discount!

E-mail: sales@probechem.com

Tech Support: tech@probechem.com

Purity & Documentation Purity: >98% (HPLC)

Biological Activity

GLS-010 (Zimberelimab, AB122) is a fully human, monoclonal immunoglobulin G4 (IgG4) anti-programmed death-1 (PD-1) antibody that shows promising efficacy and safety in advanced solid tumors.
GLS-010 (Zimberelimab) has a high affinity to PD-1 with dissociation constant (KD) of 0.175 nM.
GLS-010 (Zimberelimab) could effectively block the binding of PD-L1/2 to PD-1.
GLS-010 (Zimberelimab) showed statistically significant anti-tumor effects in the MC38 model in human PD-1 knock-in mice.

Isotype: IgG4-lambda.
Anti-[human PDCD1 (programmed cell death 1, PD-1, PD1, CD279)], human monoclonal antibody.

Physicochemical Properties

M.Wt
Formula
Appearance Solid
CAS No.
Storage
Solide Powder
-20°C 12 Months; 4°C 6 Months
In Solvent
-80°C 6 Months; -20°C 6 Months
Shipping
Solubility

10 mM in DMSO

Chemical Name/SMILES

References

Copyright © 2022 probechem.com. All Rights Reserved. probechem Copyright

Contact Us sales@probechem.com

Bulk Inquiry

* Indicates a Required FieldYour information is safe with us.

  • *Product name:
  • *Applicant name:
  • *Email address:
  • *Organization name:
  • *Requested quantity:
  • *Country:
  • *Additional Information:

Get Quote

* Indicates a Required FieldYour information is safe with us.

  • *Product name:
  • *Applicant name:
  • *Email address:
  • *Organization name:
  • *Requested quantity:
  • *Country:
  • Additional Information: